查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2134981

全球抗憂鬱症研發管線分析 - 2026 年（第二季洞察與臨床試驗）

Global Depression Drug Pipeline Analysis 2026 (Q2 Insights & Clinical Trials)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 148 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

憂鬱症仍然是全球最常見的精神疾病之一，對醫療保健系統、雇主和社會造成沉重負擔。儘管目前已有多種抗憂鬱症療法，但許多患者仍面臨治療效果不佳、起效緩慢、復發或持續性難治性憂鬱症。在此背景下，人們正加強研發療效更佳、起效更快、安全性更高的新型療法。

憂鬱症研發管線分析市場涵蓋臨床實驗試驗、臨床開發項目、競爭情報、管線基準分析、許可活動和策略研究舉措等方面的療法評估。製藥公司、生技公司、投資者、研究機構和醫療保健相關人員越來越依賴研發管線分析來評估新興機會、監控競爭對手的活動並了解未來的市場趨勢。對精準精神病學、新型作用機制、生物標記驅動的藥物發現以及下一代神經精神療法的日益關注，預計將在預測期內推動市場持續擴張。目前，超過75家公司參與了重度憂鬱症的研究，同樣有大量的候選藥物處於不同的研發階段，這反映了該行業對創新的堅定承諾。

市場促進因素

全球憂鬱症負擔日益加重

  • 推動市場發展的主要因素之一是憂鬱症及相關情緒障礙在各年齡層的盛行率不斷上升。人們對心理健康的日益關注、診斷率的提高以及對憂鬱症相關經濟負擔的認知不斷加深，都促使醫療系統和製藥公司加大對新療法的研發投入。
  • 對更有效的治療方法的巨大未滿足需求，持續推動著憂鬱症治療領域的研究和開發活動。

人們越來越重視新的作用機制。

  • 傳統抗憂鬱症通常需要數週才能顯現臨床療效，並非所有患者都能獲得充分的症狀緩解。因此，製藥公司正在研發針對不同於傳統神經通路、神經傳導物質系統和神經可塑性機制的療法。
  • 我們的開發平臺越來越側重於麩胺酸系統調節、神經活性類固醇、迷幻藥啟發的療法、神經發炎路徑以及其他旨在改善治療效果的創新方法。

臨床研發活動活性化

  • 憂鬱症藥物的研發管線依然活躍，許多療法正處於藥物發現、臨床前研究、I期、II期和III期臨床試驗的各個階段。研究機構和製藥公司持續投入大量資金，用於評估新型化合物、聯合治療和個人化治療方案。
  • 臨床試驗數量的增加導致對研發管線資訊、競爭情報和策略發展分析的需求顯著上升。

拓展策略夥伴關係和授權業務

  • 在憂鬱症藥物的研發過程中，夥伴關係、收購、授權協議和共同開發契約的重要性日益凸顯。大型製藥公司經常與生物技術創新者合作，以獲取有前景的化合物和新興技術。
  • 這些策略性措施有助於產品線多元化，並加速新療法候選藥物進入後期研發階段。近期針對憂鬱症和精神疾病治療的行業交易進一步凸顯了該治療領域的濃厚商業性價值。

市場限制因素

臨床試驗失敗率高

  • 由於精神疾病的生物機制複雜，抗憂鬱症的研發仍面臨挑戰。許多有前景的候選藥物在臨床試驗中未能展現出足夠的療效，導致研發風險增加和重大損失。
  • 憂鬱症藥物領域近期後期遭遇的挫折清楚地表明，將科學假設轉化為成功的治療結果是多麼困難。

法規的複雜性

  • 治療精神疾病的新療法通常需要廣泛的臨床檢驗，以確定其安全性、有效性和長期療效。監管機構對核准標準非常嚴格，尤其對於那些涉及新作用機製或創新療法的療法。
  • 開發週期延長和監管要求的變化會導致開發成本增加和商業化進程延遲。

來自現有療法的競爭壓力

  • 憂鬱症治療市場目前由眾多廣泛銷售且價格相對低廉的非專利抗憂鬱症主導。新研發的產品必須展現出顯著的臨床優勢，才能證明其較高價格的合理性並獲得市場認可。
  • 與現有療法的競爭可能會限制某些臨床實驗藥物的商業性機會。

目錄

第1章：引言

  • 調查方法
  • 調查範圍
    • 分析：按公司
    • 分析：按發展階段
    • 分析：按干預類型分類
    • 分析：按臨床試驗狀態
    • 分析：按地區
  • 數據來源和檢驗
  • 定義和假設

第2章 疾病概述

  • 疾病分類
  • 病因和風險因素
  • 症狀和臨床觀察
  • 診斷
  • 目前治療狀況
  • 流行病學和疾病負擔
  • 未滿足的臨床需求

第3章執行摘要

  • 臨床階段產品線概覽
  • 按開發階段分類的管道分佈
  • 臨床試驗活動中的主要公司
  • 主要臨床實驗藥物和療法
  • 各地區臨床試驗現狀
  • 管道構建中的關鍵趨勢和發現

第4章：低壓管道動態

  • 因素
  • 約束條件
  • 正在醞釀中的商業機會

第5章 管道分析/預測

  • 管道分析：按公司分類
    • Johnson & Johnson
    • Sage Therapeutics
    • Biogen
    • Neurocrine Biosciences
    • AbbVie
  • 管線分析：依開發階段分類
    • 第一階段
    • 第一階段
    • 第一/二期
    • 第二階段
    • 第二/三期
    • 第三階段
  • 管道分析：依干預類型分類
    • 製藥
    • 生物
    • 基因
  • 產品線分析：依疾病/患者群分類
    • 重度憂鬱症
    • 難治性憂鬱症
    • 產後憂鬱症
    • 其他憂鬱症
  • 管線分析：依臨床試驗進展
    • 我們尚未開始招募參與者。
    • 招募測試對象
    • 目前已暫停招募參與者。
    • 完成
    • 取消/撤回/暫停
  • 管道分析：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 臨床試驗和病患分析
    • 按註冊患者人數統計的臨床試驗
    • 依研究設計進行的臨床試驗
    • 患者年齡要求
    • 關於患者性別的參與要求
  • 贊助和合作關係分析
    • 主要商業贊助商
    • 主要學術和研究贊助商
    • 主要合作夥伴組織
    • 贊助商和合作研究者分析
  • 近期和未來管道趨勢
    • 近期啟動的臨床試驗
    • 目前正在招募受試者的臨床試驗
    • 近期完成的臨床試驗
    • 大型後期臨床試驗接近完成
    • 近期已發表結果的臨床試驗

第6章：公司簡介

  • Johnson & Johnson
  • Sage Therapeutics
  • Biogen
  • Neurocrine Biosciences
  • AbbVie

第7章 圖表清單

第8章：圖表清單

簡介目錄
Product Code: KSI-008822

Depression remains one of the most prevalent mental health disorders worldwide and represents a significant burden on healthcare systems, employers, and society. Despite the availability of numerous antidepressant therapies, a large proportion of patients continue to experience inadequate treatment response, delayed therapeutic effects, relapse, or treatment-resistant depression. These limitations have intensified research efforts focused on discovering novel therapeutic approaches capable of delivering improved efficacy, faster onset of action, and better safety profiles.

The depression drug pipeline analysis market encompasses the assessment of investigational therapies, clinical development programs, competitive intelligence, pipeline benchmarking, licensing activities, and strategic research initiatives. Pharmaceutical companies, biotechnology firms, investors, research institutions, and healthcare stakeholders increasingly rely on pipeline analysis to evaluate emerging opportunities, monitor competitive developments, and identify future market trends. The growing emphasis on precision psychiatry, novel mechanisms of action, biomarker-driven drug development, and next-generation neuropsychiatric therapies is expected to support sustained market expansion over the forecast period. Major depressive disorder research currently includes more than 75 companies and a similarly large number of pipeline drug candidates across various stages of development, reflecting strong industry commitment to innovation.

Market Drivers

Rising Global Burden of Depression

  • One of the primary factors driving the market is the increasing prevalence of depression and related mood disorders across all age groups. Rising mental health awareness, greater diagnosis rates, and increasing recognition of the economic burden associated with depression are encouraging healthcare systems and pharmaceutical companies to invest in new treatment options.
  • The substantial unmet clinical need for more effective therapies continues to stimulate research and development activities across the depression treatment landscape.

Growing Focus on Novel Mechanisms of Action

  • Traditional antidepressants often require several weeks to achieve clinical benefit and may not provide adequate symptom relief for all patients. As a result, drug developers are pursuing therapies that target alternative neurological pathways, neurotransmitter systems, and neuroplasticity mechanisms.
  • Pipeline candidates increasingly focus on glutamatergic modulation, neuroactive steroids, psychedelic-inspired therapies, neuroinflammation pathways, and other innovative approaches designed to improve treatment outcomes.

Increasing Clinical Development Activity

  • The depression drug pipeline remains highly active, with numerous therapies progressing through discovery, preclinical, Phase I, Phase II, and Phase III development stages. Research organizations and pharmaceutical companies continue to invest heavily in evaluating novel compounds, combination therapies, and personalized treatment approaches.
  • The growing volume of clinical trials is generating significant demand for pipeline intelligence, competitive assessment, and strategic development analysis.

Expansion of Strategic Collaborations and Licensing

  • Partnerships, acquisitions, licensing agreements, and co-development arrangements are becoming increasingly important in depression drug development. Large pharmaceutical companies frequently collaborate with biotechnology innovators to gain access to promising compounds and emerging technologies.
  • Such strategic activities support pipeline diversification and accelerate the advancement of novel therapeutic candidates into later stages of development. Recent industry transactions targeting depression and psychiatric therapies further highlight strong commercial interest in this therapeutic area.

Market Restraints

High Clinical Failure Rates

  • Depression drug development remains challenging due to the complex biological mechanisms underlying psychiatric disorders. Many promising candidates fail to demonstrate sufficient efficacy during clinical trials, resulting in high development risks and substantial financial losses.
  • Recent late-stage setbacks within the depression drug sector illustrate the difficulty of translating scientific hypotheses into successful therapeutic outcomes.

Regulatory Complexity

  • Novel psychiatric therapies often require extensive clinical validation to demonstrate safety, efficacy, and long-term benefit. Regulatory agencies maintain rigorous standards for approval, particularly for therapies involving new mechanisms of action or emerging treatment modalities.
  • Lengthy development timelines and evolving regulatory requirements can increase development costs and delay commercialization.

Competitive Pressure from Established Therapies

  • The depression treatment market includes numerous generic antidepressants that are widely available and relatively inexpensive. New pipeline products must demonstrate meaningful clinical advantages to justify premium pricing and achieve market adoption.
  • Competition from established therapies may limit commercial opportunities for some investigational products.

Technology and Segment Insights

  • The global depression drug pipeline analysis market can be segmented by development stage, molecule type, mechanism of action, route of administration, end user, and geography.
  • By development stage, the market includes discovery, preclinical, Phase I, Phase II, Phase III, regulatory review, and post-approval pipeline assessment. Mid-stage and late-stage clinical candidates receive significant attention due to their higher probability of commercialization and strategic value. Current pipeline activity spans all development stages, with a substantial number of candidates progressing through clinical evaluation.
  • By molecule type, the market includes small molecules, biologics, peptides, gene-based therapies, neuroactive steroids, and emerging psychiatric treatment platforms. Small molecules continue to dominate development programs, although biologics and innovative therapeutic modalities are gaining increasing attention.
  • By mechanism of action, the market includes serotonin modulators, glutamate pathway modulators, NMDA receptor-targeted therapies, GABA receptor modulators, neuroplasticity-enhancing agents, psychedelic-inspired compounds, and other novel approaches. The diversification of therapeutic mechanisms reflects industry efforts to address limitations associated with conventional antidepressants.
  • By route of administration, the market includes oral, injectable, intranasal, intravenous, and other delivery methods. Oral therapies remain the most common development category due to patient convenience and broad clinical applicability. However, alternative delivery methods are increasingly being explored to improve treatment response and speed of onset.
  • By end user, the market serves pharmaceutical companies, biotechnology firms, contract research organizations, academic institutions, investors, healthcare consulting firms, and strategic intelligence providers. Pharmaceutical companies represent the largest user segment due to their ongoing need for competitive monitoring and portfolio optimization.
  • Technological advances in artificial intelligence, machine learning, biomarker discovery, genomic analysis, and digital health platforms are improving the efficiency of target identification and drug development. These innovations are supporting more sophisticated pipeline evaluation and accelerating therapeutic discovery efforts.
  • Geographically, North America dominates the market due to extensive pharmaceutical research activity, strong mental health awareness, significant healthcare expenditure, and the presence of major industry participants. Europe maintains a substantial market share supported by active clinical research programs and favorable innovation ecosystems. Asia-Pacific is expected to experience rapid growth owing to expanding pharmaceutical capabilities, increasing healthcare investments, and rising awareness of mental health disorders.

Competitive and Strategic Outlook

  • The depression drug pipeline analysis market is characterized by intensive research activity, strategic collaborations, and continuous innovation. Numerous pharmaceutical and biotechnology companies are actively developing therapies designed to improve treatment outcomes for patients with major depressive disorder and treatment-resistant depression.
  • Competitive strategies increasingly focus on identifying differentiated mechanisms of action, leveraging biomarker-guided approaches, integrating artificial intelligence into drug discovery, and pursuing targeted acquisitions to strengthen neuroscience portfolios. Industry participants are also expanding investments in precision psychiatry, digital therapeutics integration, and next-generation neuropsychiatric treatment platforms.
  • The competitive landscape is expected to remain dynamic as new clinical data emerge and promising pipeline candidates progress toward commercialization. Organizations that successfully develop therapies with faster onset, improved efficacy, and durable treatment benefits are likely to gain significant market advantages.

Conclusion

  • The global depression drug pipeline analysis market is poised for strong growth through 2031, supported by increasing prevalence of depressive disorders, rising investment in psychiatric drug development, expanding clinical trial activity, and growing demand for innovative treatment approaches. The shift toward novel mechanisms of action, precision medicine strategies, and advanced therapeutic platforms is reshaping the future of depression treatment. While challenges related to clinical failure rates, regulatory complexity, and competitive pressures remain, ongoing scientific innovation and strategic industry investment are expected to create substantial opportunities across the depression drug development landscape.

Key Benefits of this Report

  • Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
  • Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
  • Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
  • Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
  • Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

  • Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

  • Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
  • Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
  • Competitive positioning, strategies, and market share evaluation, and trade analysis
  • Revenue growth and forecast assessment across segments and regions
  • Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Research Methodology
  • 1.2. Research Scope
    • 1.2.1. Analysis by Company
    • 1.2.2. Analysis by Development Phase
    • 1.2.3. Analysis by Intervention Type
    • 1.2.4. Analysis by Clinical Trial Status
    • 1.2.5. Analysis by Geography
  • 1.3. Data Sources and Validation
  • 1.4. Definitions and Assumptions

2. DISEASE OVERVIEW

  • 2.1. Introduction
  • 2.2. Disease Classification
  • 2.3. Causes and Risk Factors
  • 2.4. Symptoms and Clinical Manifestations
  • 2.5. Diagnosis
  • 2.6. Current Treatment Landscape
  • 2.7. Epidemiology and Disease Burden
  • 2.8. Unmet Clinical Needs

3. EXECUTIVE SUMMARY

  • 3.1. Clinical-Stage Pipeline Overview
  • 3.2. Pipeline Distribution by Development Phase
  • 3.3. Leading Companies by Clinical Trial Activity
  • 3.4. Leading Investigational Drugs and Interventions
  • 3.5. Geographic Clinical Trial Landscape
  • 3.6. Key Pipeline Trends and Findings

4. DEPRESSION PIPELINE DYNAMICS

  • 4.1. Drivers
  • 4.2. Restraints
  • 4.3. Pipeline Opportunities

5. PIPELINE ANALYSIS / OUTLOOK

  • 5.1. PIPELINE ANALYSIS BY COMPANY
    • 5.1.1. Johnson & Johnson
    • 5.1.2. Sage Therapeutics
    • 5.1.3. Biogen
    • 5.1.4. Neurocrine Biosciences
    • 5.1.5. AbbVie
  • 5.2. PIPELINE ANALYSIS BY DEVELOPMENT PHASE
    • 5.2.1. Early Phase I
    • 5.2.2. Phase I
    • 5.2.3. Phase I/II
    • 5.2.4. Phase II
    • 5.2.5. Phase II/III
    • 5.2.6. Phase III
  • 5.3. PIPELINE ANALYSIS BY INTERVENTION TYPE
    • 5.3.1. Drug
    • 5.3.2. Biological
    • 5.3.3. Genetic
  • 5.4. PIPELINE ANALYSIS BY DISEASE / PATIENT SEGMENT
    • 5.4.1. Major Depressive Disorder
    • 5.4.2. Treatment-Resistant Depression
    • 5.4.3. Postpartum Depression
    • 5.4.4. Other Depressive Disorders
  • 5.5. PIPELINE ANALYSIS BY CLINICAL TRIAL STATUS
    • 5.5.1. Not Yet Recruiting
    • 5.5.2. Recruiting
    • 5.5.3. Active, Not Recruiting
    • 5.5.4. Completed
    • 5.5.5. Terminated / Withdrawn / Suspended
  • 5.6. PIPELINE ANALYSIS BY GEOGRAPHY
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia-Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa
  • 5.7. CLINICAL TRIAL AND PATIENT ANALYSIS
    • 5.7.1. Clinical Trials by Patient Enrollment
    • 5.7.2. Clinical Trials by Study Design
    • 5.7.3. Patient Age Eligibility
    • 5.7.4. Patient Sex Eligibility
  • 5.8. SPONSOR AND COLLABORATION ANALYSIS
    • 5.8.1. Leading Commercial Sponsors
    • 5.8.2. Leading Academic and Research Sponsors
    • 5.8.3. Leading Collaborating Organizations
    • 5.8.4. Sponsor-Collaborator Analysis
  • 5.9. RECENT AND UPCOMING PIPELINE ACTIVITY
    • 5.9.1. Recently Initiated Clinical Trials
    • 5.9.2. Newly Recruiting Clinical Trials
    • 5.9.3. Recently Completed Clinical Trials
    • 5.9.4. Late-Stage Trials Approaching Primary Completion
    • 5.9.5. Trials with Recently Posted Results

6. COMPANY PROFILES

  • 6.1. Johnson & Johnson
  • 6.2. Sage Therapeutics
  • 6.3. Biogen
  • 6.4. Neurocrine Biosciences
  • 6.5. AbbVie

7. LIST OF TABLES

8. LIST OF FIGURES